5-FU Micronization: Anti-Solvent Ratios & Ripening Control
Solvent-Antisolvent Ratio Thresholds for 5-Fluorouracil Micronization and Ostwald Ripening Control
In the production of micronized 5-fluorouracil (5-FU), also referred to as 5-fluoro uracil or 5-fluoropyrimidine-2,4-dione, the solvent-antisolvent ratio is the primary lever controlling particle size distribution and long-term suspension stability. For procurement managers evaluating pharmaceutical-grade 5-fluorouracil API as a drop-in replacement, understanding these process parameters ensures batch-to-batch consistency. Our field data indicate that a dimethyl sulfoxide (DMSO)/water system at a 1:8 volumetric ratio yields a median particle size (D50) of 2–5 µm, but this is highly sensitive to the addition rate. Rapid antisolvent injection (above 50 mL/min) often triggers localized supersaturation spikes, leading to broad distributions and accelerated Ostwald ripening. A controlled, submerged feed at 10–15 mL/min with high-shear mixing maintains a narrower span. One non-standard parameter we monitor is the residual DMSO content in the slurry, which, if above 0.5% w/w, can plasticize the amorphous domains and promote crystal growth during holding. This is rarely discussed in standard literature but is critical for oncology research formulations requiring long-term stability.
For those working with fluorouracil API in generic drug development, the anti-solvent ratio must also account for the polymorphic form. 5-FU exists in two anhydrous forms (I and II) and a hemihydrate. The 1:8 ratio favors the metastable Form I, which has higher solubility but is prone to ripening. To mitigate this, we introduce a secondary ripening inhibitor—typically 0.1% w/w hydroxypropyl methylcellulose (HPMC)—which adsorbs onto crystal faces and reduces the rate of molecular exchange. This approach aligns with findings in liquid antisolvent precipitation studies for poorly soluble drugs, where stabilizers are essential for ocular or injectable delivery. Our process engineers have validated that this inhibitor does not interfere with the subsequent formulation steps for Adrucil intermediate equivalents. When sourcing 5-fluorouracil, always request the particle size distribution (PSD) data and confirm the anti-solvent ratio used, as it directly impacts the dissolution profile and bioavailability.
Polymorphic Habit Formation and Exothermic Management During Anti-Solvent Precipitation
The crystallization of 5-fluorouracil via anti-solvent precipitation is exothermic, and the heat of mixing can influence polymorphic habit. In our production campaigns, we have observed that a temperature rise of 8–12°C occurs when DMSO and water are mixed at the 1:8 ratio without external cooling. This adiabatic heating can shift the nucleation pathway from Form I to the more stable Form II, which exhibits a plate-like morphology and slower dissolution. For a drop-in replacement to match the performance benchmark of the original product, the polymorph must be controlled. We employ jacketed reactors with a cooling capacity to maintain the mixture at 5±2°C, which favors the formation of fine, equant crystals of Form I. This is particularly important for 5-fluoropyrimidine-2,4-dione impurity profile considerations, as Form II can incorporate solvent molecules, leading to elevated residual solvent levels. A related article on 5-fluoropyrimidine-2,4-dione impurity profile for drop-in replacement details how we manage these impurities to meet ICH Q3C guidelines.
Another field observation is the habit modification caused by trace metal ions. In one campaign, a stainless-steel reactor contributed iron ions at sub-ppm levels, which resulted in elongated, needle-like crystals that were difficult to filter. This habit change also increased the specific surface area, leading to higher electrostatic charging and poor flowability. We now use glass-lined or Hastelloy equipment and monitor the conductivity of the antisolvent water to ensure it remains below 1 µS/cm. For procurement managers, this translates to a more consistent product with predictable handling characteristics. When evaluating a global manufacturer, inquire about their reactor materials and temperature control capabilities, as these directly affect the polymorphic purity and, consequently, the dissolution rate of the micronized 5-FU.
Filtration Cake Dewatering and Slurry Viscosity Anomalies in 5-FU Micronization
After anti-solvent precipitation, the slurry of micronized 5-fluorouracil presents unique challenges in filtration and dewatering. The needle-like or plate-like habits, combined with a broad PSD, can lead to a dense, impermeable cake that retains significant moisture. In our experience, a slurry with a D50 of 3 µm and a span of 1.8 can have a specific cake resistance of 2×10¹¹ m/kg, requiring pressure filtration at 4–6 bar to achieve a cake moisture content below 30% w/w. However, if the Ostwald ripening is not controlled, the crystal growth during holding can increase the D50 to 8–10 µm, reducing the resistance but also altering the dissolution profile. We have found that adding a small amount of ethanol (5% v/v) to the wash solvent reduces the surface tension and improves dewatering without causing agglomeration. This is a non-standard parameter that we have optimized through field trials.
Viscosity anomalies are another concern. At solid loadings above 15% w/w, the slurry can exhibit shear-thickening behavior, which complicates transfer and spray drying. We have measured apparent viscosities of 500–800 cP at low shear, dropping to 100 cP under high shear. This is attributed to the formation of a network structure by the anisotropic particles. To mitigate this, we maintain the slurry at 10–12% solids and use a continuous stirred tank to prevent settling. For those formulating 5-FU topical gels, understanding these rheological properties is essential. Our article on 5-fluorouracil topical gel formulation: solvent compatibility and rheology control provides further insights into how these particle characteristics affect final product performance. When sourcing micronized 5-FU, ask for the filtration and drying method, as it impacts the residual solvent profile and the degree of agglomeration.
Bulk Packaging and COA Parameters for Micronized 5-Fluorouracil: IBC and 210L Drum Specifications
For bulk procurement of micronized 5-fluorouracil, packaging is a critical factor in maintaining product integrity during storage and transport. We supply the product in 210L HDPE drums with double LDPE liners, each containing 25 kg net weight, or in 500 kg IBCs (Intermediate Bulk Containers) for larger campaigns. The choice between these depends on the customer's handling equipment and consumption rate. The 210L drum is standard for most pharmaceutical intermediates, but for micronized powders, we include a desiccant bag and nitrogen purge to prevent moisture uptake, which can accelerate Ostwald ripening even in the solid state. The IBC option is suitable for high-volume users and is equipped with a cone valve discharge to minimize dusting. All packaging complies with UN standards for chemical transport, but we emphasize that these are physical packaging specifications only; no claims regarding environmental certifications are made.
The Certificate of Analysis (COA) for each batch includes the following key parameters, which are critical for a drop-in replacement evaluation:
| Parameter | Specification | Typical Value |
|---|---|---|
| Assay (HPLC) | 99.0–101.0% | 99.8% |
| Particle Size (D50) | 2–5 µm | 3.2 µm |
| Particle Size (D90) | ≤10 µm | 7.5 µm |
| Polymorphic Form | Form I | Conforms |
| Residual Solvents (DMSO) | ≤0.5% | 0.12% |
| Water Content (KF) | ≤1.0% | 0.3% |
| Heavy Metals | ≤10 ppm | <5 ppm |
Please refer to the batch-specific COA for exact values. We also provide additional data on specific surface area (BET) and bulk density upon request. For procurement managers, these parameters ensure that the micronized 5-FU will perform equivalently to the original product in downstream formulation. Our quality system follows GMP standards, and we maintain full traceability from raw materials to finished product.
Frequently Asked Questions
What is the optimal anti-solvent for 5-fluorouracil micronization?
Water is the most common anti-solvent due to the low solubility of 5-FU (approximately 12 mg/mL at 25°C). However, the choice of solvent for 5-FU is critical; DMSO and dimethylformamide (DMF) are effective, but DMSO is preferred for its lower toxicity and easier removal. The ratio and addition rate must be tightly controlled to achieve the desired particle size and polymorph.
How does agitation speed affect particle size distribution?
Agitation speed directly influences the mixing intensity and supersaturation homogeneity. At low speeds (below 200 rpm), macro-mixing is poor, leading to broad PSDs. At very high speeds (above 800 rpm), particle breakage can occur, generating fines that promote Ostwald ripening. We have found an optimal range of 400–600 rpm for a 1:8 DMSO/water system, yielding a D50 of 2–5 µm with a span below 1.5.
What washing protocols remove residual organics effectively?
After filtration, the cake is washed with purified water at a ratio of 2:1 (v/w) to displace the mother liquor. For DMSO, a second wash with a 5% ethanol/water mixture can reduce residual DMSO to below 0.1%. The wash solvent temperature should be 5–10°C to minimize crystal dissolution and ripening. The effectiveness is verified by GC headspace analysis on the dried powder.
Is 5-FU chemo considered a strong chemo?
5-Fluorouracil is an antimetabolite chemotherapy drug, and its strength depends on the dose and regimen. It is commonly used for solid tumors and is considered moderately strong, with side effects that are manageable with proper monitoring. However, this article focuses on the API manufacturing and quality aspects, not clinical use.
How many cycles of 5-fluorouracil are typically administered?
Treatment cycles vary by indication, but a common regimen is once weekly for 6–8 weeks, or as part of a combination therapy. This information is for context only; procurement managers should refer to clinical guidelines for therapeutic use.
How do you prepare 5-fluorouracil for formulation?
5-FU is typically dissolved in a suitable solvent (e.g., DMSO for stock solutions) and then incorporated into the final dosage form. For micronized powders, direct dispersion in a gel or suspension is possible. The preparation method must consider the polymorphic form and particle size to ensure consistent release.
Is fluorouracil chemo or immunotherapy?
5-Fluorouracil is a chemotherapy drug, not an immunotherapy. It works by inhibiting thymidylate synthase, disrupting DNA synthesis. This distinction is important for procurement, as the API is used in cytotoxic manufacturing facilities with appropriate containment.
Sourcing and Technical Support
As a global manufacturer of 5-fluorouracil API, NINGBO INNO PHARMCHEM CO.,LTD. provides micronized 5-FU with consistent quality and technical support for drop-in replacement applications. Our process understanding of anti-solvent ratios, Ostwald ripening control, and polymorph management ensures that your formulations meet performance benchmarks. We offer bulk quantities in 210L drums or IBCs, with comprehensive COA documentation. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.